Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Liver Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Smoking 1Sarcoma 1Recurrence 1Precancerous Conditions 1Pharyngeal Neoplasms 1Peritoneal Neoplasms 1Paranasal Sinus Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Glioblastoma 1Colonic Neoplasms 1Breast Neoplasms 1Biomarker Change Linked to Breast Cancer 1

Interventions

Sorafenib 7Radiosurgery 6Bevacizumab 6pembrolizumab 4Oxaliplatin 4Cryosurgery 4atezolizumab 3Radiotherapy, Conformal 3Nivolumab 3Ipilimumab 3Fluorouracil 3Cyclophosphamide 3tremelimumab 2spartalizumab 2lenvatinib 2fludarabine 2Leucovorin 2Injections 2Gemcitabine 2Everolimus 2Epirubicin 2Doxorubicin 2Celecoxib 2Carboplatin 2Capecitabine 2yttrium chloride 1vofatamab 1toripalimab 1tocilizumab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Liver Neoplasms × Celecoxib × Clear all
NCT00293436 2012-09-17

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

University of California, San Francisco

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00057980 2012-06-11

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

Northwestern University

Phase 1/2 Completed
8 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡